Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

54 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A Phase I Study of Romidepsin in Combination With Gemcitabine, Oxaliplatin, and Dexamethasone in Patients With Relapsed or Refractory Aggressive Lymphomas Enriched for T-Cell Lymphomas.
Foley N, Riedell PA, Bartlett NL, Cashen AF, Kahl BS, Fehniger TA, Fischer A, Moreno C, Liu J, Carson KR, Mehta-Shah N. Foley N, et al. Among authors: riedell pa. Clin Lymphoma Myeloma Leuk. 2024 Dec 4:S2152-2650(24)02436-4. doi: 10.1016/j.clml.2024.11.015. Online ahead of print. Clin Lymphoma Myeloma Leuk. 2024. PMID: 39725584
Establishing meaningful change thresholds for European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire CLL-specific module domain scores: An analysis based on the TRANSCEND CLL 004 study in patients with relapsed or refractory chronic lymphocytic leukaemia or small lymphocytic lymphoma.
Eliason L, Fofana F, Wang L, Riedell PA, Guo S. Eliason L, et al. Among authors: riedell pa. EJHaem. 2024 Oct 7;5(6):1165-1172. doi: 10.1002/jha2.1007. eCollection 2024 Dec. EJHaem. 2024. PMID: 39691275 Free PMC article.
Lisocabtagene Maraleucel for Relapsed/Refractory Large B-Cell Lymphoma: A Cell Therapy Consortium Real-World Analysis.
Riedell PA, Grady CB, Nastoupil LJ, Luna De Abia A, Ahmed N, Maziarz RT, Hu M, Brower J, Hwang WT, Schuster SJ, Chen AI, Oluwole OO, Bachanova V, McGuirk JP, Perales MA, Bishop MR, Porter DL. Riedell PA, et al. Blood Adv. 2024 Dec 10:bloodadvances.2024014164. doi: 10.1182/bloodadvances.2024014164. Online ahead of print. Blood Adv. 2024. PMID: 39657136
Optimizing the post-CAR T monitoring period in recipients of axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel.
Ahmed N, Wesson W, Lutfi F, Porter DL, Bachanova V, Nastoupil LJ, Perales MA, Maziarz RT, Brower J, Shah GL, Chen AI, Oluwole OO, Schuster SJ, Bishop MR, McGuirk JP, Riedell PA. Ahmed N, et al. Among authors: riedell pa. Blood Adv. 2024 Oct 22;8(20):5346-5354. doi: 10.1182/bloodadvances.2023012549. Blood Adv. 2024. PMID: 39042880 Free PMC article.
BsAbs before CD19 CAR-T: full speed ahead!
Riedell PA. Riedell PA. Blood. 2024 Jul 18;144(3):249-251. doi: 10.1182/blood.2024025048. Blood. 2024. PMID: 39023866 No abstract available.
Outcomes of patients with secondary central nervous system lymphoma treated with chimeric antigen receptor T-cell therapy: A CIBMTR analysis.
Epperla N, Hashmi H, Ahn KW, Allbee-Johnson M, Chen AI, Wirk B, Kanakry JA, Lekakis L, Kharfan-Dabaja MA, Scordo M, Riedell PA, Jain T, Shadman M, Sauter C, Hamadani M, Herrera AF, Ahmed S. Epperla N, et al. Among authors: riedell pa. Br J Haematol. 2024 Sep;205(3):1202-1207. doi: 10.1111/bjh.19569. Epub 2024 May 26. Br J Haematol. 2024. PMID: 38797526 No abstract available.
54 results